401 related articles for article (PubMed ID: 11788817)
21. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
22. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
23. Clinical role of FDG PET in evaluation of cancer patients.
Kostakoglu L; Agress H; Goldsmith SJ
Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
[TBL] [Abstract][Full Text] [Related]
24. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
25. [Indications for the use of PET or PET/CT in patients with breast cancer].
Bernsdorf M; Graff J
Ugeskr Laeger; 2011 Oct; 173(42):2638-41. PubMed ID: 22027163
[TBL] [Abstract][Full Text] [Related]
26. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET.
Reinhardt MJ; Ehritt-Braun C; Vogelgesang D; Ihling C; Högerle S; Mix M; Moser E; Krause TM
Radiology; 2001 Mar; 218(3):776-82. PubMed ID: 11230656
[TBL] [Abstract][Full Text] [Related]
27. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
28. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography for the diagnosis of breast cancer.
Rosé C; Dose J; Avril N
Nucl Med Commun; 2002 Jul; 23(7):613-8. PubMed ID: 12089482
[TBL] [Abstract][Full Text] [Related]
30. Current and future uses of positron emission tomography in breast cancer imaging.
Eubank WB; Mankoff DA
Semin Nucl Med; 2004 Jul; 34(3):224-40. PubMed ID: 15202103
[TBL] [Abstract][Full Text] [Related]
31. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
[TBL] [Abstract][Full Text] [Related]
32. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
Crowe JP; Adler LP; Shenk RR; Sunshine J
Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
[TBL] [Abstract][Full Text] [Related]
34. Nuclear medicine advances in breast cancer imaging.
Bombardieri E; Crippa F; Baio SM; Peeters BA; Greco M; Pauwels EK
Tumori; 2001; 87(5):277-87. PubMed ID: 11765174
[TBL] [Abstract][Full Text] [Related]
35. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
36. Emerging role of PET in the diagnosis and staging of lung cancer.
Coates G; Skehan SJ
Can Respir J; 1999; 6(2):145-52. PubMed ID: 10322097
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for positron emission tomography in breast cancer staging?
Hodgson NC; Gulenchyn KY
J Clin Oncol; 2008 Feb; 26(5):712-20. PubMed ID: 18258978
[TBL] [Abstract][Full Text] [Related]
38. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
[TBL] [Abstract][Full Text] [Related]
40. Evolving role of positron emission tomography in breast cancer imaging.
Eubank WB; Mankoff DA
Semin Nucl Med; 2005 Apr; 35(2):84-99. PubMed ID: 15765372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
